Literature DB >> 2144687

Structure-function relationships in sheep, mouse, and human prostaglandin endoperoxide G/H synthases.

W L Smith1, D L DeWitt, S A Kraemer, M J Andrews, T Hla, T Maciag, T Shimokawa.   

Abstract

Our studies are designed to determine which amino acid residues are involved in catalyzing the cyclooxygenase and hydroperoxidase activities of prostaglandin endoperoxide (PGG/H) synthase. We have deduced from complementary (c)DNAs the amino acid sequences of the sheep and mouse PGG/H synthases, and a portion of the human PGG/H synthase. These enzymes have amino acid sequences which are about 90% identical. Sequence similarities with putative heme binding regions of myeloperoxidase and thyroid peroxidase suggest that the sequence TI(L)WLREHNRV of PGG/H synthase contains the histidine (His309) which is the proximal heme ligand; the distal heme ligand may be His226 which is found in the sequence 222-KALGH-226. Using site-directed mutagenesis, we have replaced Ser530, the serine residue which is acetylated by aspirin, with Ala530 and with Asn530; the Ala530 mutant has both cyclooxygenase and hydroperoxidase activity, while the Asn530 mutant lacks cyclooxygenase activity but retains hydroperoxidase activity. These results establish that the hydroxyl group of Ser530 is not essential for catalysis or substrate binding and suggest that a bulky group at position 530, such as that introduced by aspirin acetylation, prevents arachidonate binding to the cyclooxygenase active site. Finally, we have found that tetranitromethane causes irreversible inactivation of cyclooxygenase activity and that the enzyme is protected from inactivation when ibuprofen is included in the reaction mixture. These results suggest that there is an essential tyrosine at the active site of PGG/H synthase.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144687

Source DB:  PubMed          Journal:  Adv Prostaglandin Thromboxane Leukot Res        ISSN: 0732-8141


  7 in total

1.  cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.

Authors:  M K O'Banion; V D Winn; D A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

2.  Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood.

Authors:  Gang Zhou; Gopal K Marathe; Belinda Willard; Thomas M McIntyre
Journal:  J Biol Chem       Date:  2011-08-15       Impact factor: 5.157

3.  Inhibition of DDX3 and COX-2 by forskolin and evaluation of anti-proliferative, pro-apoptotic effects on cervical cancer cells: molecular modelling and in vitro approaches.

Authors:  Doneti Ravinder; Shailima Rampogu; Gangappa Dharmapuri; Akbar Pasha; Keun Woo Lee; Smita C Pawar
Journal:  Med Oncol       Date:  2022-04-28       Impact factor: 3.064

4.  QSAR and conformational analysis of the antiinflammatory agent amfenac and analogues.

Authors:  J Ruiz; M López; J Milà; E Lozoya; J J Lozano; R Pouplana
Journal:  J Comput Aided Mol Des       Date:  1993-04       Impact factor: 3.686

5.  Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2).

Authors:  Gang Zhou; Gopal K Marathe; Jaana Hartiala; Stanley L Hazen; Hooman Allayee; W H Wilson Tang; Thomas M McIntyre
Journal:  J Biol Chem       Date:  2013-03-18       Impact factor: 5.157

6.  The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer.

Authors:  Thomas E Adrian; Rene Hennig; Helmut Friess; Xianzhong Ding
Journal:  PPAR Res       Date:  2009-01-27       Impact factor: 4.964

7.  Lipopolysaccharide Cross-Tolerance Delays Platelet-Activating Factor-Induced Sudden Death in Swiss Albino Mice: Involvement of Cyclooxygenase in Cross-Tolerance.

Authors:  Shancy Petsel Jacob; Chikkamenahalli Lakshminarayana Lakshmikanth; Vyala Hanumanthareddy Chaithra; Titus Ruth Shantha Kumari; Chu-Huang Chen; Thomas M McIntyre; Gopal Kedihitlu Marathe
Journal:  PLoS One       Date:  2016-04-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.